Neogen Chemicals 2026: ₹161 crore preferential allotment

What Neogen Chemicals announced

Neogen Chemicals Limited completed a preferential allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, an entity classified under the promoter group. The company said the shares were allotted at ₹1,610 per share, taking the total proceeds to ₹161 crore. The approval for allotment was granted by the Fund Raising Committee of the Board of Directors on April 18, 2026. Neogen also disclosed that regulatory approvals from BSE Limited and the National Stock Exchange of India Limited were received on April 17, 2026.

The equity shares have a face value of ₹10 each and were issued at a premium of ₹1,600 per share. The issue price, as disclosed, was set at a 17.02% premium to the floor price of ₹1,375.82, computed under Regulation 164 of the SEBI ICDR Regulations. The company further stated that the shares allotted to the promoter group category are subject to an 18-month lock-in from the date of trading approval, under Regulation 167 of the SEBI ICDR Regulations.

Preferential issue details and shareholding impact

Neogen said the preferential allotment resulted in Cadamba Solutions Private Limited holding 10,00,000 equity shares, representing a 3.65% stake in the company. The disclosures also noted that the investor’s pre-allotment holding was 0%. The company positioned the transaction as a promoter-group infusion executed through a preferential issue route and completed after the required exchange approvals.

In a separate set of disclosures referenced in the provided material, Neogen’s earlier communications indicated fundraising proposals that were still subject to approvals. One board-meeting intimation stated that the board would consider raising funds through a preferential issue of equity shares, with pricing to be determined under SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018. The company also said the proposal would require necessary approvals, including shareholder approval at a general meeting or via postal ballot, along with regulatory and statutory clearances where applicable.

Board approvals, EGM, and the approval chain

Neogen announced an Extraordinary General Meeting (EGM) scheduled for March 29, 2026, for shareholder approval of the preferential issue. E-voting for the resolution was scheduled to be open from March 26 to March 28, 2026. The preferential issue was conducted pursuant to the special resolution passed by members at the EGM held on March 29, 2026, according to the company’s disclosures.

Separately, Neogen also disclosed the outcome of a board meeting held on February 11, 2026. The board approved the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board also granted in-principle approval to raise up to ₹150 crore through a preferential issue of equity shares to the promoter group, subject to regulatory sanctions, and approved the grant of 50,200 stock options through the Nomination and Remuneration Committee.

Market reaction and broker coverage

On March 9, 2026, Neogen Chemicals’ stock advanced 1.18% to ₹1,381.70 after the company announced that its board would meet on Saturday, March 7, 2026, to consider raising funds through a preferential issue. The company’s update around that period emphasised that the fundraising plan and pricing would be evaluated under SEBI regulations and would remain subject to shareholder and other approvals.

The broader news flow also included a March 19, 2026 update stating that AMSEC started coverage of India’s Gujarat Fluorochemicals and Neogen Chemicals with a “buy” view, as referenced in the provided text.

Other financing: ₹200 crore NCD placement

Alongside the equity fundraising route, the provided material references Neogen raising ₹200 crore via a private placement of non-convertible debentures (NCDs). The NCDs were described as fully paid, secured, rupee-denominated instruments carrying a fixed interest rate of 10.50% and a tenure of up to 30 months, with monthly interest payments. The issuance was rated CRISIL A with a “Negative” outlook and was described as fully subscribed by institutional investors. The debentures were set to be listed on the BSE.

Neogen stated that the proceeds would be used to enhance financial flexibility while executing key expansion projects. The disclosures also said a portion of proceeds would support reconstruction of the organic chemicals plant at Dahej SEZ, cited as being affected by a recent disruption, and help bridge operational needs until insurance claims are settled.

Insurance receipts linked to a fire incident

The provided text also references insurance payouts connected to a fire loss. It mentions Neogen Chemicals receiving ₹60 crore for the fire incident and an additional ₹30 crore insurance payment for the fire loss. These disclosures indicate cash inflows from insurance while the company worked through restoration and rebuilding activities.

Key numbers at a glance

Why this matters for investors

The preferential allotment is a promoter-group capital infusion completed after stock-exchange approvals, with the shares carrying an 18-month lock-in. The disclosed pricing mechanics reference the SEBI ICDR framework and a premium to the floor price.

At the same time, the company’s financing activity is not limited to equity. The referenced ₹200 crore NCD issue adds a debt leg to Neogen’s funding mix, with specific terms disclosed on pricing, tenure, rating, and planned use. The insurance receipts cited in the material provide additional context around liquidity support following the fire-related loss, alongside the reconstruction mention for the Dahej SEZ plant.

Conclusion

Neogen Chemicals’ completed preferential allotment at ₹1,610 per share raised ₹161 crore from promoter-group entity Cadamba Solutions, following the March 29, 2026 shareholder resolution and April 2026 exchange approvals. The company’s disclosures also point to parallel fundraising through ₹200 crore of NCDs and insurance receipts linked to the fire loss. The next data points for investors, based on the provided material, remain the implementation and utilisation of raised funds and the operational progress referenced around reconstruction and expansion activity.